196 related articles for article (PubMed ID: 38323738)
1. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
2. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
[TBL] [Abstract][Full Text] [Related]
3. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
[TBL] [Abstract][Full Text] [Related]
4. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
[TBL] [Abstract][Full Text] [Related]
5. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
[TBL] [Abstract][Full Text] [Related]
6. Still grasping at straws: donanemab in Alzheimer's disease.
Doggrell SA
Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295
[TBL] [Abstract][Full Text] [Related]
7. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
8. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA
JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300
[TBL] [Abstract][Full Text] [Related]
9. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
[TBL] [Abstract][Full Text] [Related]
10. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease.
Shukla AK; Misra S
J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):25-29. PubMed ID: 38053285
[TBL] [Abstract][Full Text] [Related]
11. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
13. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
Song T; Wang Y; Silverglate BD; Grossberg GT
Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
[TBL] [Abstract][Full Text] [Related]
15. Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials.
Rashad A; Rasool A; Shaheryar M; Sarfraz A; Sarfraz Z; Robles-Velasco K; Cherrez-Ojeda I
Healthcare (Basel); 2022 Dec; 11(1):. PubMed ID: 36611492
[TBL] [Abstract][Full Text] [Related]
16. Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Wessels AM; Dennehy EB; Dowsett SA; Dickson SP; Hendrix SB
Neurol Clin Pract; 2023 Apr; 13(2):e200127. PubMed ID: 36891463
[TBL] [Abstract][Full Text] [Related]
17. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
18. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
Ebell MH; Barry HC; Baduni K; Grasso G
Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
[TBL] [Abstract][Full Text] [Related]
19. Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Wang J; Shcherbinin S; Sims JR; Chigutsa E
Alzheimers Dement (N Y); 2023; 9(2):e12404. PubMed ID: 37388759
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Høilund-Carlsen PF; Alavi A; Castellani RJ; Neve RL; Perry G; Revheim ME; Barrio JR
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
